ArticleScientific reports2026
Clinical significance of serum levels of 14-3-3β protein in patients with non-small cell lung cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Lung cancer diagnosis still relies on imaging and tissue sampling, which can be invasive and costly. Moreover, anatomic staging alone does not fully capture biological heterogeneity. Therefore, minimally invasive blood biomarkers are needed to support diagnosis and risk stratification. We integrated public transcriptomic data analyses with an independent serum-based enzyme-linked immunosorbent assay (ELISA) validation cohort. Using the Gene Expression Omnibus (GEO) dataset GSE40275, we compared RNA expression of tyrosine 3‑monooxygenase/tryptophan 5‑monooxygenase activation protein β (14‑3‑3β, encoded by the YWHAB gene) between 43 healthy control subjects and patients with distinct lung cancer pathological subtypes, including 11 cases of lung adenocarcinoma (LUAD) and 5 cases of lung squamous cell carcinoma (LUSC).Two additional GEO datasets, GSE29013 (30 LUAD and 25 LUSC patients) and GSE43580 (77 LUAD and 73 LUSC patients), were utilized to validate the differential 14-3-3β RNA expression between LUAD and LUSC subtypes. In the GSE29013 cohort, subgroup analyses were performed stratified by tumor stage, disease progression status, and clinical outcomes; Kaplan-Meier Plotter was applied to assess the associations of 14-3-3β expression with overall survival (OS) and post-progression survival (PPS). For serum-level validation, peripheral blood samples from 15 LUAD patients, 21 LUSC patients, and 32 healthy controls were examined via ELISA, with receiver operating characteristic curve analysis conducted to evaluate its diagnostic performance via calculation of the area under the curve (AUC). 14-3-3β RNA expression was higher in LUAD and LUSC than in controls (both p < 0.0001) and higher in LUSC than in LUAD (P = 0.005), which was confirmed in GSE29013 (P = 0.0140) and GSE43580 (P = 0.0222). In GSE29013, higher 14-3-3β expression was associated with tumor progression (P = 0.0440) and death (P = 0.0091), and predicted shorter OS (HR = 1.21; P = 0.0043) and PPS (HR = 1.55; P = 9.7e-05). Serum 14-3-3β levels were increased in LUAD and LUSC, yielding an AUC of 0.93 with 80.6% sensitivity and 100% specificity at a cutoff of 43.04 ng/mL. Across tissue transcriptomes and serum validation, 14-3-3β is associated with lung cancer presence, histological subtype, and survival outcomes, supporting its potential as a minimally invasive adjunct biomarker for diagnosis and prognostic assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.